Abstract
Despite the availability of powerful ‘omic’ tools, the slowing rate of discovery of new antibacterials, together with the rising problem of microbial resistance, does not guarantee that we will not revert to the pre-antibiotic era, as nowadays virtually every pathogen has been found to resist every antibiotic in clinical use. The identification and study of new inhibitable targets or finding new ways to inhibit already known targets appear to be two possible research options to obtain new antibiotics. These options are not mutually exclusive and, given the wealth of new data provided by genome-wide analysis and its related techniques (proteomics and interactomics among them), there is a need to devote sufficient effort and funding into selecting new targets and to apply rational research and screening strategies to overcome the initial lack of success in the search for these clearly needed drugs.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call